Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes

Haematologica. 2024 Apr 11. doi: 10.3324/haematol.2022.281396. Online ahead of print.

¹ Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110.
² Department of Leukemia, MD Anderson Cancer Center, Houston, Texas 77030.
³ Department of Neurosurgery, Washington University School of Medicine, St. Louis, Missouri 63110.
⁴ Department of Pathology, Washington University School of Medicine, St. Louis, Missouri 63110.
⁵ Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St. Louis, Missouri 63110.
⁶ Albert Einstein College of Medicine, Bronx, New York 10461.
⁷ Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110; A2 Biotherapeutics, Agoura Hills, California 91301 (work completed while at Washington University). jwelch@a2biotherapeutics.com.

Abstract

Not available.